Canadian medical technology company Arrayus Technologies has received Health Canada approval for its MRI-guided Focused Ultrasound System to ablate uterine fibroid tissue.
The Focused Ultrasound System uses high-precision acoustic energy to target and treat tissue deep within the body, eliminating the need for incisions or general anaesthesia.
It enables biological effects, including thermal or mechanical tissue destruction, immunomodulation, drug delivery and radiosensitisation.
The technology combines advanced imaging and therapy monitoring with a unique full phased array, intuitive treatment planning tools and real-time therapy monitoring, to ensure superior treatment control and flexibility.
Also, the system enables clinicians to customise treatments based on individual disease characteristics, ensuring precision while protecting nearby healthy tissue.
Arrayus CEO James O’Reilly said: “I am incredibly proud of our team for achieving this monumental first milestone. Securing Health Canada approval marks a pivotal moment in the evolution of our technology but it’s only the beginning.
“Our platform has the potential to transform patient care across multiple medical specialities.
“We are committed to pushing the boundaries of medical innovation to reduce the burden on the healthcare system and improve patient outcomes worldwide.”
Arrayus Technologies is a spin-out of Sunnybrook Research Institute, focused on developing, manufacturing, and commercialising focused ultrasound technology for oncology.
The Health Canada approval follows a first-in-human clinical trial and enables Canadian healthcare providers to provide a safe, non-invasive alternative to traditional surgical options.
Currently, the company is conducting clinical trials to assess the use of its focused ultrasound system in several oncological settings.
Also, it is working with healthcare professionals, researchers, and industry partners to explore its use in neurology, women’s health, and beyond.
